CDC in U.S. and FDA recommend pausing Johnson & Johnson COVID-19 Vaccine rollout over blood clots
Six cases in women between ages 18 and 48 of cerebral venous sinus thrombosis (CVST) bloods clots have been identified in the U.S 6-13 days following Johnson and Johnson’s COVID-19 vaccine. The blood clots were observed in combination with low levels of blood platelets.
Source:
Biospace Inc.
SPS commentary:
Like the AstraZeneca vaccine, the Janssen vaccine uses a viral vector platform. In Janssen’s case researchers used adenovirus type 26, the same as used in Russia’s Gamaleya Research Institute vaccine, known as Sputnik.